Document is current
Any future updates will be listed below
-
Authors
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Davis, Christal N. https://orcid.org/0000-0003-3974-5598
Feinn, Richard
Jinwala, Zeal https://orcid.org/0009-0005-5062-0827
Khan, Yousef https://orcid.org/0009-0002-3093-3947
Oikonomou, Ariadni
Silva-Lopez, Damaris
Burton, Isabel
Dixon, Morgan
Milone, Jackson
Ramirez, Sarah
Shifman, Naomi
Levey, Daniel https://orcid.org/0000-0001-8431-9569
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Hartwell, Emily E. https://orcid.org/0000-0002-5137-9714
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (I01 BX004820, IK2 CX002336)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA028292)
- License Information
-
More Information
Article History
Received: 23 October 2023
Accepted: 10 April 2024
First Online: 4 June 2024
Competing interests
: H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the past three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka and Pear Therapeutics. H.R.K. and J.G. hold US patent 10,900,082, titled ‘Genotype-guided dosing of opioid agonists’, issued 26 January 2021. The other authors declare no competing interests.
